2. Search Result
Search Result
Results for "

C27

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Peptides

1

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3418
    CKLF1-C27

    		CCR ERK Inflammation/Immunology
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .
    CKLF1-C27
  • HY-CE01242
    C27:0-CoA

    C27:0-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    C27:0-CoA (C27:0-coenzyme A) is a coenzyme A derivative .
    C27:0-CoA
  • HY-P3418A
    CKLF1-C27 TFA

    		CCR ERK Inflammation/Immunology
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .
    CKLF1-C27 TFA
  • HY-108043
    AZD-2327

    		Opioid Receptor Neurological Disease
    AZD-2327 is a potent and selective δ-opioid receptor agonist. AZD-2327 binds to the human opioid receptor (Ki = 0.49 and 0.75 nM and EC50 = 24 and 9.2 nM at the C27 and F27 isoforms, respectively). AZD-2327 shows selectivity of >1000-fold over the human μ- and κ-opioid receptor subtypes as well as >130 other receptors and channels. AZD-2327 exhibits antidepressant and anxiolytic activities and can be used for the research of neurological disease .
    AZD-2327
  • HY-161748
    PD-1/PD-L1-IN-46

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-46 (compound (R)-C27 ) is an PD-1/PD-L1 antagonist with IC50 value of 18.66 nM .
    PD-1/PD-L1-IN-46
  • HY-123357
    IMM-H004

    		Apoptosis Neurological Disease
    IMM-H004, a coumarin derivative, possesses neuroprotective and potent free radical scavenging abilities. IMM-H004 significantly inhibits amyloid-β (Aβ)-induced cytotoxicity and apoptosis, offering potential value for research into neurodegenerative diseases such as Alzheimer's disease. Additionally, IMM-H004 is also capable of effectively blocking the calcium mobilization and chemotaxis induced by CKLF1-C27 (HY-P3418), thereby alleviating asthmatic pathological changes in the lung tissue of CKLF1 transgenic mice .
    IMM-H004
  • HY-W414824
    3β,7β-Dihydroxy-5-cholestenoic acid

    		Endogenous Metabolite Neurological Disease
    3β,7β-Dihydroxy-5-cholestenoic acid is a C27 acid that displays elevated levels in Niemann-Pick type C and Niemann-Pick type B diseases, contributing to toxicity in oculomotor neurons. It is synthesized from 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid (3βH,7O-CA) through the enzymatic action of hydroxysteroid 11-β dehydrogenase 1.
    3β,7β-Dihydroxy-5-cholestenoic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: